Aegerion Pharmaceuticals, Inc. has appointed Craig E. Fraser as president, U.S. Mr. Fraser was most recently vice president, Global Disease Areas at Pfizer, responsible for the commercial development and global marketing for the specialty cardiovascular, anti-bacterial, anti-fungal, gastrointestinal and anti-viral disease areas. Prior to Pfizer, Mr. Fraser was vice president and global business manager at Wyeth, where he led the institutional/infectious disease business. Mr. Fraser also held several commercial positions at Johnson & Johnson, most recently as vice president, Commercial Operations and Oncology Sales and Marketing.
"Craig joins Aegerion at a critical time, as we plan for the anticipated approval and launch of lomitapide in 2012," said chief executive officer Marc D. Beer. "His experience managing the commercial development of a broad array of products in major global companies, specifically in the cardiovascular and highly specialized disease areas, ideally positions him as the lead of our U.S. commercial team. Craig has the proven ability to facilitate a successful launch and grow revenues effectively, and we eagerly welcome him to our growing management team."
